Center-Authored Papers

Filters: Author is Hudecek, Michael  [Clear All Filters]
2009
Brown CE, Starr R, Martinez C, Aguilar B, D'Apuzzo M, Todorov I, Shih C-C, Badie B, Hudecek M, Riddell SR et al..  2009.  Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.. Cancer research. 69(23):8886-93. Abstract
Nishida T, Hudecek M, Kostic A, Bleakley M, Warren EH, Maloney DG, Storb R, Riddell SR.  2009.  Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(14):4759-68. Abstract
2010
Bleakley M, Otterud BE, Richardt JL, Mollerup AD, Hudecek M, Nishida T, Chaney CN, Warren EH, Leppert MF, Riddell SR.  2010.  Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.. Blood. 115(23):4923-33. Abstract
Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang W-C, Greisman HA et al..  2010.  The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.. Blood. 116(22):4532-41. Abstract
2012
Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH et al..  2012.  Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen.. Blood. 119(23):5492-501. Abstract
Turtle CJ, Hudecek M, Jensen MC, Riddell SR.  2012.  Engineered T cells for anti-cancer therapy.. Current opinion in immunology. 24(5):633-9. Abstract
2013
Hudecek M, Lupo-Stanghellini M-T, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR.  2013.  Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(12):3153-3164. Abstract
2014
Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, Hudecek M, Maloney DG, Turtle CJ.  2014.  Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.. Cancer journal (Sudbury, Mass.). 20(2):141-4. Abstract
2015
Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, Kosasih PL, Rader C, Riddell SR.  2015.  Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.. Cancer immunology research. 3(2):206-16. Abstract
2016
Turtle CJ, Hanafi L-A, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM et al..  2016.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.. The Journal of clinical investigation. 126(6):2123-38. Abstract
Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, Sadelain M, Liu L, Jensen MC, Riddell SR et al..  2016.  Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.. The Journal of clinical investigation. 126(11):4262-4272. Abstract
Turtle CJ, Hanafi L-A, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X et al..  2016.  Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.. Science translational medicine. 8(355):355ra116. Abstract